Moderna (MRNA) Accumulated Depreciation & Amortization: 2017-2025
Historic Accumulated Depreciation & Amortization for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to $51.0 million.
- Moderna's Accumulated Depreciation & Amortization changed negligibly% to $51.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $204.0 million, marking a year-over-year decrease of 37.99%. This contributed to the annual value of $185.0 million for FY2024, which is 70.02% down from last year.
- Per Moderna's latest filing, its Accumulated Depreciation & Amortization stood at $51.0 million for Q3 2025, which was down 8.93% from $56.0 million recorded in Q2 2025.
- Over the past 5 years, Moderna's Accumulated Depreciation & Amortization peaked at $246.0 million during Q3 2023, and registered a low of $15.0 million during Q1 2021.
- Moreover, its 3-year median value for Accumulated Depreciation & Amortization was $56.0 million (2025), whereas its average is $86.1 million.
- Per our database at Business Quant, Moderna's Accumulated Depreciation & Amortization skyrocketed by 1,014.29% in 2021 and then plummeted by 79.27% in 2024.
- Quarterly analysis of 5 years shows Moderna's Accumulated Depreciation & Amortization stood at $78.0 million in 2021, then rose by 2.56% to $80.0 million in 2022, then skyrocketed by 153.75% to $203.0 million in 2023, then crashed by 70.94% to $59.0 million in 2024, then remained steady at $51.0 million in 2025.
- Its Accumulated Depreciation & Amortization stands at $51.0 million for Q3 2025, versus $56.0 million for Q2 2025 and $38.0 million for Q1 2025.